

Research in Your Backyard

Developing Cures, Creating Jobs



**PHARMACEUTICAL
CLINICAL TRIALS IN
MICHIGAN**

Dots show locations of clinical trials in the state.

PhARMA

Executive Summary

Clinical Trials in Michigan

- Biopharmaceutical research companies are conducting or have conducted more than 3,400 clinical trials of new medicines in collaboration with the state's clinical research centers, university medical schools and hospitals (1999 to present).
- Of the more than 3,400 clinical trials, 1,725 target or have targeted the nation's six most debilitating chronic diseases—asthma, cancer, diabetes, heart disease, mental illnesses and stroke.

Economic Benefits of Clinical Trials in Michigan

- Biopharmaceutical research companies have been an important source of jobs, tax revenue and research spending in Michigan.
- A study by Archstone Consulting found that in 2008 the industry supported nearly 95,000 jobs throughout the state.
- Employees working directly for the companies were paid \$1.6 billion, leading to \$57 million in state taxes and more than \$388 million in federal taxation.

"The nation's biopharmaceutical research companies are providing a steady source of revenue to local research institutions all over the state at a time when Michigan needs as many boosts to its economy as it can get. The industry, in collaboration with the state's university medical schools and science centers, local hospitals and contract research organizations, has conducted nearly 3,500 clinical trials of new prescription drugs since 1999. Today, companies and their local partners are conducting nearly 400 trials of new medicines. That's good news for some chronic disease sufferers who are still seeking the treatments best for them and it is certainly welcome news to Michigan's research collaborators since clinical trials account for 45 to 75 percent of the \$1.2 billion average cost of developing just one new novel treatment."

—Stephen Rapundalo
President & CEO, MichBio

“The obvious impact of having so many clinical trials of novel new medicines in Michigan is the prospect of improved health care and the badly needed boost given the state’s economy. But we also should consider the prestige and excitement of having so much cutting-edge biopharmaceutical research underway. It means our neighbors and friends in communities all over the state include dedicated scientists and researchers who are focused on research that could dramatically improve the health of patients all over the world.”

—Linda Burghardt
Executive Director, NAMI Michigan

- Biopharmaceutical research firms that year also invested \$1.1 billion in research and development and supported \$20.5 billion in products and services.
- Company employees in Michigan include life sciences researchers, management executives, office and administrative support workers, engineers, architects, computer and math experts and sales representatives.

About Clinical Trials

- In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.
- Clinical tests of new drugs are conducted in three phases and account for an average of seven of the 10 to 15 years it takes to take a new drug from development to patients.
- Clinical trials for a given drug or treatment involve thousands of volunteer patient participants, and the generation of tens of thousands of pages of technical and scientific data.
- Clinical trials are responsible for 45 to 75 percent of the \$1.2 billion average cost of developing one new cutting-edge biotechnology medicine.
- Biopharmaceutical companies frequently hire local research institutions to conduct the tests.
- For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them.

Clinical Trials in Michigan since 1999— Completed and Active

All Clinical Trials	Six Major Chronic Diseases
3,424	1,725

Source: www.clinicaltrials.gov

Note: Search criteria = Michigan, Phase I, II, III; industry only.
Search performed 4/10/2012.

- All clinical trials must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conducted and patient rights are protected.

- Clinical trial progress reports must be submitted at least annually to the FDA and the IRB.
- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

Clinical Trials in Michigan Communities

Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Alpena	—	—	3	3	—	1
Ann Arbor	—	96	7	10	5	4
Bay City	1	4	3	3	—	—
Dearborn	—	7	10	5	—	1
Detroit	—	165	7	24	1	6
East Lansing/Lansing	—	15	2	8	5	2
Farmington Hills	—	10	1	—	1	—
Flint	—	3	12	6	—	3
Grand Blanc	1	—	—	2	—	2
Grand Rapids	—	26	2	8	2	2
Kalamazoo	—	9	10	9	2	3
Lapeer	—	1	1	1	—	—
Midland	—	—	2	3	—	2
Novi	2	3	3	2	1	1
Rochester	1	—	1	—	5	—
Royal Oak	—	5	1	9	—	2
Saginaw	—	3	4	11	—	3
Southfield	—	8	8	5	—	1
Traverse City	—	1	1	1	3	—
Troy	1	1	3	4	2	1
Warren	—	2	1	1	—	1
Wyoming	1	3	—	1	—	1
Ypsilanti	1	3	—	1	—	1

Source: www.clinicaltrials.gov

Note: Search criteria = Michigan, Phase I, II, III; industry only. Search performed 4/10/2012. See Appendix for detailed information about these clinical trials. Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city.

Clinical Trials and Chronic Diseases

- Chronic diseases pose the greatest threats to our nation's health and our ability to treat and prevent medical conditions.
- According to the Centers for Disease Control and Prevention, today, in the United States:
 - Patients with chronic diseases account for 75 cents of every dollar spent on health care.
 - Chronic diseases are the leading cause of death and disability.
 - Chronic diseases are a leading driver of rising health care costs with expenses totaling billions of dollars every year.
- Biopharmaceutical research companies are developing new medicines to help treat those conditions that are taking an unprecedented toll on American lives, and many of these medicines are being tested today in clinical trials throughout Michigan.
- Since 1999, biopharmaceutical research companies are sponsoring or have sponsored 1,725 clinical trials of potential new medicines in Michigan alone for asthma, cancer, heart disease, stroke, diabetes and mental illnesses. Of these trials, 385 are either not yet recruiting or are just now seeking Michigan patients.
- Many of the state's clinical tests involve collaborations with such respected local institutions as the University of Michigan Medical School in Ann Arbor, the Barbara Ann Karmanos Cancer Institute and the Henry Ford Health System in Detroit, the William Beaumont Hospital at Wayne State University in Royal Oak, the Helen

DeVos Children's Hospital and Spectrum Health Hospitals in Grand Rapids, and the Michigan - Cardiovascular Institute in Saginaw.

- Many of the medicines being clinically tested here are new-generation biotechnology treatments.

"Biopharmaceutical research companies are conducting clinical trials from Detroit to Grand Rapids to Traverse City to Saginaw and beyond. The trials that are underway, and the ones that have already been conducted, bolster state and local economies of many different communities."

—Wendy Block

Director of Health Policy & Human Resources, Michigan Chamber of Commerce

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	30	5
Cancer	994	265
Diabetes	220	33
Heart Disease	201	45
Mental Illness	243	28
Stroke	37	9
Total	1,725	385

Source: www.clinicaltrials.gov

Note: Search criteria = Michigan, Phase I, II, III; industry only. Search performed 4/10/2012. Some clinical trials appear in more than one disease category.

Clinical Trials in Michigan

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the \$1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It's essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines used by patients. The FDA is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	30	5
Cancer	994	265
Diabetes	220	33
Heart Disease	201	45
Mental Illness	243	28
Stroke	37	9
Total	1,725	385

Source: www.clinicaltrials.gov

Note: Search criteria = Michigan, Phase I, II, III; industry only. Search performed 4/10/2012. Some clinical trials appear in more than one disease category.

Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites around the country. In Michigan, biopharmaceutical companies have the opportunity of conducting trials at the states' well-respected university medical schools, comprehensive cancer centers and clinical trial research centers. According to *U.S. News and World Report*, the University of Michigan-Ann Arbor Medical School ranked 10th, Wayne State University School of Medicine ranked 78th and Michigan State University College of Human Medicine ranked 87th among last year's top 100 research-oriented medical schools in the United States. Other ranked universities include the Michigan State University College of Osteopathic Medicine.

Asthma is a debilitating condition for more than 24 million Americans, including 7 million children under the age of 18. The toll is also severe in Michigan—more than 230,000 children and 700,000 adults suffer from asthma, according to the Michigan Department of Community Health.

Currently, five clinical trials of new asthma medicines are recruiting patients in Michigan. Trials are being conducted at **Grand Blanc Medical** in Grand Blanc and at locations in Bay City, Novi, Rochester and Ypsilanti.

Cancer, the second leading cause of death in the United States, now afflicts nearly 12 million Americans, according to the National Cancer Institute. In Michigan, nearly 58,000 new cancer cases will be diagnosed this year and 20,430 victims in the state will die, according to the American Cancer Society.

Currently, 265 clinical trials of new cancer medicines are recruiting patients in Michigan. Biopharmaceutical companies are collaborating on the tests with such prominent institutions as the **University of Michigan Comprehensive Cancer Center** in Ann Arbor, the **Barbara Ann Karmanos Cancer Institute** at **Wayne State University** and the **Henry Ford Medical Center** in Detroit, **Michigan State University's Breslin Cancer Center** in East Lansing, and the **Grand Rapids Clinical Oncology Program**.

Diabetes affects more than 25 million Americans—about 8 percent of the U.S. population—and nearly one-third are unaware they have the disease. In Michigan, about 9 percent of adults have been diagnosed with diabetes and prevalence has increased 15 percent over the last five years, according to the Michigan Department of Community Health.

Currently, 33 diabetes clinical tests are seeking patients in Michigan. The trials are being conducted at **Henry Ford Hospital** in Royal Oak, **Hurley Medical Center** in Flint, the **Borgess Diabetes Center** in Kalamazoo, **Providence Park Clinical Research** in Novi, **Saginaw Valley Medical**

Research Group in Saginaw, and **KMED Research** in St. Clair Shores.

Heart disease and stroke are the first and fourth leading disease causes of death in the United States and the first and third in Michigan. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Michigan, in 2009, more than 23,000 residents died from some form of heart disease and more than 4,400 died from a stroke, according to the Michigan Department of Community Health.

Currently, 45 heart disease and 9 stroke clinical tests are seeking patients in Michigan. The trials are being conducted at the **Michigan Cardiovascular Institute** in Saginaw, **Michigan Heart** in Ypsilanti, the **University of Michigan Medical Center** in Ann Arbor, the **Detroit Medical Center Cardiovascular Institute**, **William Beaumont Hospital** in Royal Oak, **Munson Medical Center** in Traverse City, and **Spectrum Health** in Grand Rapids.

Mental illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Michigan, nearly 348,000 adults live with serious mental illness and about 112,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 28 clinical trials for mental illness are recruiting patients in Michigan. The trials are taking place at the **Rochester Center for Behavioral Medicine** in Rochester Hills, and in Ann Arbor, the **Michigan Head, Pain & Neurological Institute** and the **VA Healthcare System**.

Physicians and patients can find out about clinical trials being conducted across the state in collaboration with local institutions by accessing www.clinicaltrials.gov, a database sponsored by the National Institutes of Health. Information on medicines in development is also available on www.phrma.org, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA).

What is the Clinical Trial Experience?

Clinical trials are research studies which grant participants early access to new drugs, treatments, and therapies that are being developed to help combat chronic, serious and life threatening diseases. By volunteering for a clinical trial, patients take an active role in their healthcare by helping researchers test new medical treatments, and helping to find better ways of using existing treatments so they will be more effective, easier to use, and result in fewer or more tolerable side effects. In Michigan alone, thousands of clinical trials are taking place to study diseases like asthma, cancer, diabetes, heart disease, mental illness, and stroke.

Phases of Clinical Trials

There are three phases of testing used to evaluate new drugs and treatments:

Phase I—This phase is designed to test the safety of a new drug or treatment. Researchers test the drug on a small group of people (20-80) and evaluate safety aspects of the drug, such as safe dosage range, the best way of administering the treatment (pill form vs. a shot for example), and identifying what, if any, side effects present themselves.

Phase II—This phase is designed to test efficacy and to further measure safety. The treatment is given to a larger group of people (100-300) to make sure the treatment

works correctly, and to try to identify any less-common side effects, which may appear when more people are tested. This phase is usually placebo-controlled and double-blinded, meaning neither the patient nor the doctor knows whether the patient is getting the placebo or the real treatment.

Phase III—This phase is meant to confirm efficacy and safety information, monitor known side effects, and compare the experimental treatment to commonly used ones to see which work better. A large group (1000-3000) receives this treatment, and like Phase II, it is usually placebo-controlled and double-blinded.

Learning About and Accessing Clinical Trials

There are several ways patients can access information about clinical trials. Healthcare providers are aware of clinical trials being conducted at hospitals, universities, and other leading healthcare facilities, and can be valuable sources of information for patients looking to participate. Patients can also turn to hospitals' and universities' websites to see what studies are being conducted in their area, and what the eligibility criteria are for each trial. More information about clinical trials and volunteering can be found at <http://centerwatch.com/>, a PhRMA-recommended website.

What to Expect

Treatments for clinical trials usually take place in a doctor's office. Patients may need to devote more time to doctor's visits and physical exams than they would normally. They may also have additional responsibilities, like keeping a daily log of their health. All prospective participants must sign an informed consent document saying they understand the clinical trial is research, and that they can leave the trial at any time. Once they have consulted with their healthcare providers, patients can reach out via phone or email to express interest in participating, at which point a pre-screening interview will take place. If the patient matches the trial's criteria, they will then be able to enroll in the study.

Patient Expenses

Patients should always ask during their pre-screening interviews what it will cost them to participate in a clinical trial. Sponsors for clinical trials will usually pay for all research-related costs and any additional testing or doctor's visits the trial requires. Patients or their insurance companies may be asked to pay for any routine treatments that they would normally undergo for their disease. However, some health plans do not pay for these costs once a patient joins the trial. Patients should be sure to check with the clinic conducting the trial to find out if they or their insurance companies will be charged with any

fees, and should make sure their insurance companies will cover the costs of routine exams if they join a trial.

Non-local patients should be sure to look into the sponsoring clinic's policy on patient living arrangements. The National Cancer Institute, for example, makes patients responsible for their own travel costs for the initial screening visits. Once a patient is enrolled, the Institute will pay for transportation costs for all subsequent trial-related visits. These patients will receive a small per diem for food and lodging. The policy will differ from clinic to clinic.

New Generation Medicines in Development

Many of the medicines being tested in Michigan are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and vaccines today. And Michigan is one of the states where extensive new-generation research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict, preempt and prevent it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology

is being used in biotechnology research to provide drug-delivery systems, new treatments and diagnostics.

Many of the medicines in clinical testing at Michigan medical schools and research centers feature these technologies. For example:

- A monoclonal antibody for the treatment of cancer.
- An antisense medicine for the treatment of cancer.
- A recombinant fusion protein to treat age-related macular degeneration and diabetic macular edema.
- A monoclonal antibody in the pipeline targets lupus and various types of cancer.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma.

These are only a portion of the examples of new ways the nation's biopharmaceutical companies and Michigan research institutions are working together to attack disease. The biotechnology medicines and vaccines in development promise to push the frontiers of science and potentially bring more and better treatments to patients.

Conclusion

Biopharmaceutical companies' close collaboration with clinicians and research institutions in Michigan benefits patients, the state's economy and the advancement of science and patient care. Clinical trial work is good business for the state's medical schools and clinical research centers and the medicines being tested are often cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What's more, Michiganders contemplating participation in clinical trials in consultation with their doctors, have a wide range of choices—nearly 400 tests of new medicines for the six most debilitating chronic diseases in America are underway in communities large and small all over the state and they need patient volunteers.

The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials						
	Discovery/ Preclinical Testing	Phase I	Phase II	Phase III	FDA	Phase IV
Years	6.5	1.5	2	3.5	1.5	
Test Population	Laboratory and animal studies	20 to 100 healthy volunteers	100 to 500 patient volunteers	1,000 to 5,000 patient volunteers	Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use		
Success Rate	5,000 compounds evaluated	5 enter trials			1 approved	

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are usually developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug

Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I. These tests usually involve about 20 to 100 healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

Clinical Trials, Phase II. In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness and determine the early side effect profile.

Clinical Trials, Phase III. This phase usually involves 1,000 to 5,000 patients in clinics and

hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated \$49.5 billion in research and development in 2011.

The Good News – Many Clinical Trials are Still Recruiting

There are 385 clinical trials recruiting in Michigan. These trials target the top six chronic diseases and other debilitating diseases affecting Americans and Michiganders.

Clinical Trials in Michigan Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Alpena	—	—	3	3	—	1
Ann Arbor	—	96	7	10	5	4
Bay City	1	4	3	3	—	—
Dearborn	—	7	10	5	—	1
Detroit	—	165	7	24	1	6
East Lansing/Lansing	—	15	2	8	5	2
Farmington Hills	—	10	1	—	1	—
Flint	—	3	12	6	—	3
Grand Blanc	1	—	—	2	—	2
Grand Rapids	—	26	2	8	2	2
Kalamazoo	—	9	10	9	2	3
Lapeer	—	1	1	1	—	—
Midland	—	—	2	3	—	2
Novi	2	3	3	2	1	1
Rochester	1	—	1	—	5	—
Royal Oak	—	5	1	9	—	2
Saginaw	—	3	4	11	—	3
Southfield	—	8	8	5	—	1
Traverse City	—	1	1	1	3	—
Troy	1	1	3	4	2	1
Warren	—	2	1	1	—	1
Wyoming	1	3	—	1	—	1
Ypsilanti	1	3	—	1	—	1

Source: www.clinicaltrials.gov

Note: Search criteria = Michigan, Phase I, II, III; industry only. Search performed 4/10/2012. See Appendix for detailed information about these clinical trials. Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city.

The Good News—Many Clinical Trials are Still Recruiting

(continued)

Asthma—Leading Institutions Conducting Clinical Trials

Grand Blanc Medical, Grand Blanc

Cancer—Leading Institutions Conducting Clinical Trials

Ann Arbor Hematology Oncology Associates,

Ann Arbor

Barbara Ann Karmanos Cancer Institute at Wayne State

University, Detroit

Bay Regional Medical Center, Bay City

C.S. Mott Children's Hospital, Ann Arbor

Cancer & Hematology Centers of Western Michigan,

Grand Rapids

Children's Hospital of Michigan, Detroit

Clinical Oncology Associates, Farmington Hills

Detroit Clinical Research Center, Farmington Hills

Grand Rapids Clinical Oncology Program,

Grand Rapids

Great Lakes Cancer Institute, Bay City

Grekin Skin Institute, Warren

Helen DeVos Children's Hospital, Grand Rapids

Henry Ford Hospital, Detroit

Henry Ford Medical Center-Columbus Center, Novi

Henry Ford Medical Center, Detroit

Henry Ford Medical Center-Fairlane, Dearborn

Henry Ford Medical Center-West Bloomfield,

West Bloomfield

Josephine Ford Cancer Center-Downriver,

Brownstone

Karmanos Cancer Institute at Farmington Hills,

Farmington Hills

KMED Research, St. Clair Shores

Lapeer Regional Medical Center, Lapeer

McLaren Regional Medical Center, Flint

Metro Health Cancer Care, Wyoming

Michigan State University Breslin Cancer Center,

East Lansing

Mid-Michigan Physicians, Lansing

Mount Clemens Regional Medical Center,

Mount Clemens

Oncology Care Associates, St. Joseph

Providence Hospital and Medical Center, Southfield

Sparrow Regional Cancer Center, Lansing

Spectrum Health Medical Group, Grand Rapids

St. John Hospital and Medical Center, Grosse Pointe

St. Joseph Mercy Hospital, Ann Arbor

St. Mary's Health Care, Grand Rapids

St. Mary's of Michigan, Saginaw

University of Michigan Comprehensive Cancer Center,

Ann Arbor

University of Michigan, Department of Neurosurgery,

Ann Arbor

West Michigan Cancer Center, Kalamazoo

William Beaumont Hospital, Royal Oak

Diabetes—Leading Institutions Conducting Clinical Trials

Alzohalli Medical Consultants, Dearborn

Apex Medical Research, Flint

Associated Internal Medicine Specialists, Battle Creek

Borgess Research Institute, Kalamazoo

Endeavor Medical Research, Alpena

Henry Ford Hospital, Detroit

Hurley Medical Center, Flint

Jasper Clinic, Kalamazoo

KMED Research, St. Clair Shores

Michigan Head Pain & Neurological Institute,

Ann Arbor

Providence Park Clinical Research, Novi

Saginaw Valley Medical Research Group, Saginaw

St. Clair Specialty Physicians, Detroit

Troy Internal Medicine, Troy

**Heart Disease and Stroke—Leading Institutions
Conducting Clinical Trials**

Bay Regional Medical Center, Bay City
Borgess Medical Center, Kalamazoo
Cardiac & Vascular Research Center of Northern
Michigan, Petoskey
Cardiovascular Consultants of East Michigan, Flint
Detroit Medical Center Cardiovascular Institute,
Detroit
Genesys Regional Medical Center, Grand Blanc
Harper University Hospital, Detroit
Henry Ford Hospital, Detroit
Jasper Clinic, Kalamazoo
Lakeland HealthCare, St. Joseph
McLaren Macomb, Mount Clemens
Michigan Cardiovascular Institute, Saginaw
Michigan Heart, Ann Arbor
Michigan Heart, Ypsilanti
Michigan State University, East Lansing
Mid-Michigan Physicians Group, Midland
Munson Medical Center, Traverse City
Spectrum Health Hospitals, Grand Rapids
St. John Hospital and Medical Center, Detroit
St. Joseph Mercy Hospital, Pontiac
St. Mary's Healthcare, Grand Rapids
Thoracic & Cardiovascular Healthcare Foundation,
Lansing
University of Michigan Health System, Ann Arbor
William Beaumont Hospital, Royal Oak

**Mental Illness—Leading Institutions
Conducting Clinical Trials**

Michigan Head, Pain & Neurological Institute,
Ann Arbor
QUEST Research Institute, Farmington Hills
Rochester Center for Behavioral Medicine,
Rochester Hills
VA Ann Arbor Healthcare System, Ann Arbor

**Stroke—Leading Institutions
Conducting Clinical Trials**

Henry Ford Hospital, Detroit
McLaren Regional Medical Center, Flint
University of Michigan Medical Center, Ann Arbor
William Beaumont Hospital, Royal Oak

Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto *www.clinicaltrials.gov*, the clinical tests database of the National Institutes of Health.

Asthma

(5 clinical trials recruiting)

Study 1:

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

<http://ClinicalTrials.gov/show/NCT01545453>

Study 2:

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

<http://ClinicalTrials.gov/show/NCT01172821>

Study 3:

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

<http://ClinicalTrials.gov/show/NCT00809757>

Study 4:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

<http://ClinicalTrials.gov/show/NCT01008410>

Study 5:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

<http://ClinicalTrials.gov/show/NCT01008423>

Cancer

(265 clinical trials recruiting)

Study 1:

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

<http://ClinicalTrials.gov/show/NCT01355302>

Study 2:

GAMMA—Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

<http://ClinicalTrials.gov/show/NCT01231347>

Study 3:

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

<http://ClinicalTrials.gov/show/NCT00858364>

Study 4:

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01188187>

Study 5:

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01217697>

Study 6:

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

<http://ClinicalTrials.gov/show/NCT01347645>

Study 7:

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

<http://ClinicalTrials.gov/show/NCT01077154>

Study 8:

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

<http://ClinicalTrials.gov/show/NCT00968968>

Study 9:

A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

<http://ClinicalTrials.gov/show/NCT01246960>

Study 10:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

<http://ClinicalTrials.gov/show/NCT00045968>

Study 11:

A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01288911>

Study 12:

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

<http://ClinicalTrials.gov/show/NCT01358877>

Study 13:

Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

<http://ClinicalTrials.gov/show/NCT00320710>

Study 14:

Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01284348>

Study 15:

EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01360840>

Study 16:

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01309126>

Study 17:

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

<http://ClinicalTrials.gov/show/NCT00878709>

Study 18:

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

<http://ClinicalTrials.gov/show/NCT01170650>

Study 19:

Immunotherapy Study for Surgically Resected Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01072981>

Study 20:

Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00840749>

Study 21:

A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast Cancer or Other Solid Tumor

<http://ClinicalTrials.gov/show/NCT01482715>

Study 22:

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01362400>

Study 23:

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01454089>

Study 24:

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01374425>

Study 25:

A Trial of E7080 (Lenvatinib) in 131I-Refractory Differentiated Thyroid Cancer

<http://ClinicalTrials.gov/show/NCT01321554>

Study 26:

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01231802>

Study 27:

Study of Patients With Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00948675>

Study 28:

ARCHER 1009: A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01360554>

Study 29:

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

<http://ClinicalTrials.gov/show/NCT01173497>

Study 30:

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

<http://ClinicalTrials.gov/show/NCT00676507>

Study 31:

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT00856375>

Study 32:

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01199367>

Study 33:

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

<http://ClinicalTrials.gov/show/NCT00790816>

Study 34:

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

<http://ClinicalTrials.gov/show/NCT01300533>

Study 35:

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

<http://ClinicalTrials.gov/show/NCT01154140>

Study 36:

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01220128>

Study 37:

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT00959127>

Study 38:

A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

<http://ClinicalTrials.gov/show/NCT01168973>

Study 39:

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

<http://ClinicalTrials.gov/show/NCT01364844>

Study 40:

A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT00585195>

Study 41:

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

<http://ClinicalTrials.gov/show/NCT01478594>

Study 42:

Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) Non-Small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01526928>

Study 43:

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

<http://ClinicalTrials.gov/show/NCT00996762>

Study 44:

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01082549>

Study 45:

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

<http://ClinicalTrials.gov/show/NCT01078649>

Study 46:

A Study for Patients With Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT00839332>

Study 47:

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT00724503>

Study 48:

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01211483>

Study 49:

Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB

<http://ClinicalTrials.gov/show/NCT01072838>

Study 50:

A Study of AMG 337 in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01253707>

Study 51:

Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

<http://ClinicalTrials.gov/show/NCT00680992>

Study 52:

A Study of Onartuzumab (MetMab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

<http://ClinicalTrials.gov/show/NCT01456325>

Study 53:

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01436214>

Study 54:

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)

<http://ClinicalTrials.gov/show/NCT01171898>

Study 55:

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

<http://ClinicalTrials.gov/show/NCT00649207>

Study 56:

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

<http://ClinicalTrials.gov/show/NCT01480583>

Study 57:

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

<http://ClinicalTrials.gov/show/NCT01290471>

Study 58:

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

<http://ClinicalTrials.gov/show/NCT00730639>

Study 59:

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01355484>

Study 60:

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

<http://ClinicalTrials.gov/show/NCT01355497>

Study 61:

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01186991>

Study 62:

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

<http://ClinicalTrials.gov/show/NCT01409135>

Study 63:

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

<http://ClinicalTrials.gov/show/NCT01497665>

Study 64:

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

<http://ClinicalTrials.gov/show/NCT01284192>

Study 65:

A Trial In Patients With Advanced Cancer And Leukemia

<http://ClinicalTrials.gov/show/NCT00878189>

Study 66:

Study of ABT-700 in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01472016>

Study 67:

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

<http://ClinicalTrials.gov/show/NCT01004224>

Study 68:

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01296243>

Study 69:

Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01335945>

Study 70:

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01137968>

Study 71:

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

<http://ClinicalTrials.gov/show/NCT01314118>

Study 72:

Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression

<http://ClinicalTrials.gov/show/NCT01111461>

Study 73:

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01268059>

Study 74:

Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

<http://ClinicalTrials.gov/show/NCT01461915>

Study 75:

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01304797>

Study 76:

A Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT00951665>

Study 77:

Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

<http://ClinicalTrials.gov/show/NCT01132664>

Study 78:

A Study for Patients With Small-Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01025284>

Study 79:

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01505530>

Study 80:

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01283373>

Study 81:

Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01193257>

Study 82:

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01308567>

Study 83:

A Study of Oral LGK974 in Patients With Melanoma and Lobular Breast Cancer

<http://ClinicalTrials.gov/show/NCT01351103>

Study 84:

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01297491>

Study 85:

Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00686959>

Study 86:

Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/ Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01493843>

Study 87:

A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

<http://ClinicalTrials.gov/show/NCT01351415>

Study 88:

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01562015>

Study 89:

Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

<http://ClinicalTrials.gov/show/NCT01307501>

Study 90:

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

<http://ClinicalTrials.gov/show/NCT01387282>

Study 91:

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

<http://ClinicalTrials.gov/show/NCT01513083>

Study 92:

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01471197>

Study 93:

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

<http://ClinicalTrials.gov/show/NCT01419197>

Study 94:

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01362296>

Study 95:

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

<http://ClinicalTrials.gov/show/NCT01363232>

Study 96:

Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

<http://ClinicalTrials.gov/show/NCT01285609>

Study 97:

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

<http://ClinicalTrials.gov/show/NCT01289041>

Study 98:

A Study of DS-2248, in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01288430>

Study 99:

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

<http://ClinicalTrials.gov/show/NCT01221077>

Study 100:

Adverse Event Toxicity Intervention Study To Evaluate The Effect Of Prophylactic Treatment And An Interrupted Dosing Schedule On The Incidence Of Adverse Events In Patients Treated With Dacomitinib (PF-00299804)

<http://ClinicalTrials.gov/show/NCT01465802>

Study 101:

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

<http://ClinicalTrials.gov/show/NCT00948467>

Study 102:

A Study in Head and Neck Cancer

<http://ClinicalTrials.gov/show/NCT01081041>

Study 103:

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-intestinal Stromal Tumour

<http://ClinicalTrials.gov/show/NCT00812240>

Study 104:

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

<http://ClinicalTrials.gov/show/NCT01273493>

Study 105:

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

<http://ClinicalTrials.gov/show/NCT00948961>

Study 106:

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01311713>

Study 107:

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01454934>

Study 108:

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

<http://ClinicalTrials.gov/show/NCT00798252>

Study 109:

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

<http://ClinicalTrials.gov/show/NCT01359696>

Study 110:

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

<http://ClinicalTrials.gov/show/NCT01231594>

Study 111:

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

<http://ClinicalTrials.gov/show/NCT00803647>

Study 112:

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

<http://ClinicalTrials.gov/show/NCT01237236>

Study 113:

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01352884>

Study 114:

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

<http://ClinicalTrials.gov/show/NCT01087970>

Study 115:

Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

<http://ClinicalTrials.gov/show/NCT00698243>

Study 116:

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

<http://ClinicalTrials.gov/show/NCT00891605>

Study 117:

A Dose-escalation Study in Subjects With Advanced Malignancies

<http://ClinicalTrials.gov/show/NCT01072266>

Study 118:

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01479465>

Study 119:

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01472198>

Study 120:

First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01323933>

Study 121:

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

<http://ClinicalTrials.gov/show/NCT00932451>

Study 122:

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT00688116>

Study 123:

A Study of IMC-RON8 in Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01119456>

Study 124:

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

<http://ClinicalTrials.gov/show/NCT00932893>

Study 125:

Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01215864>

Study 126:

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01360853>

Study 127:

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

<http://ClinicalTrials.gov/show/NCT01254630>

Study 128:

Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors

<http://ClinicalTrials.gov/show/NCT01188499>

Study 129:

Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT00942799>

Study 130:

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

<http://ClinicalTrials.gov/show/NCT01340846>

Study 131:

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

<http://ClinicalTrials.gov/show/NCT00878436>

Study 132:

A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

<http://ClinicalTrials.gov/show/NCT01546519>

Study 133:

Study to Assess Safety, Tolerability and PK of AZD1480 Alone or in Comb With Docetaxel in Patients With Solid Tumours

<http://ClinicalTrials.gov/show/NCT01112397>

Study 134:

A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

<http://ClinicalTrials.gov/show/NCT01564251>

Study 135:

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

<http://ClinicalTrials.gov/show/NCT00925743>

Study 136:

A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01345201>

Study 137:

A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01277146>

Study 138:

A Study of Ramucirumab and Paclitaxel in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01515306>

Study 139:

A Study of Ramucirumab and Docetaxel in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01567163>

Study 140:

MSC2015103B in Solid Tumors

<http://ClinicalTrials.gov/show/NCT01453387>

Study 141:

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01170897>

Study 142:

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumor

<http://ClinicalTrials.gov/show/NCT01248949>

Study 143:

Oral Azacitidine as a Single Agent and in Combination With Carboplatin or Abraxane® in Subjects With Relapsed or Refractory Solid Tumors

<http://ClinicalTrials.gov/show/NCT01478685>

Study 144:

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01160211>

Study 145:

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01033032>

Study 146:

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

<http://ClinicalTrials.gov/show/NCT01213472>

Study 147:

Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01035658>

Study 148:

Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

<http://ClinicalTrials.gov/show/NCT01292655>

Study 149:

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

<http://ClinicalTrials.gov/show/NCT00871559>

Study 150:

Study of Ruxolitinib in Pancreatic Cancer Patients

<http://ClinicalTrials.gov/show/NCT01423604>

Study 151:

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01507168>

Study 152:

Dose Escalation Study of INK1117 in Subjects With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01449370>

Study 153:

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

<http://ClinicalTrials.gov/show/NCT01428219>

Study 154:

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00884546>

Study 155:

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors

<http://ClinicalTrials.gov/show/NCT01562275>

Study 156:

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

<http://ClinicalTrials.gov/show/NCT01074970>

Study 157:

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

<http://ClinicalTrials.gov/show/NCT01413893>

Study 158:

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00927875>

Study 159:

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

<http://ClinicalTrials.gov/show/NCT00876109>

Study 160:

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

<http://ClinicalTrials.gov/show/NCT00776594>

Study 161:

Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01527487>

Study 162:

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

<http://ClinicalTrials.gov/show/NCT01450761>

Study 163:

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

<http://ClinicalTrials.gov/show/NCT01235962>

Study 164:

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors

<http://ClinicalTrials.gov/show/NCT00996892>

Study 165:

GSK1120212 Rollover Study

<http://ClinicalTrials.gov/show/NCT01376310>

Study 166:

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

<http://ClinicalTrials.gov/show/NCT01042795>

Study 167:

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

<http://ClinicalTrials.gov/show/NCT01401959>

Study 168:

Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy

<http://ClinicalTrials.gov/show/NCT00480857>

Study 169:

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

<http://ClinicalTrials.gov/show/NCT01384292>

Study 170:

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

<http://ClinicalTrials.gov/show/NCT01465659>

Study 171:

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

<http://ClinicalTrials.gov/show/NCT00929188>

Study 172:

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01321346>

Study 173:

Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

<http://ClinicalTrials.gov/show/NCT01470794>

Study 174:

Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

<http://ClinicalTrials.gov/show/NCT00690430>

Study 175:

IMA901 in Patients Receiving Sunitinib for Advanced/ Metastatic Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01265901>

Study 176:

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

<http://ClinicalTrials.gov/show/NCT00882609>

Study 177:

A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

<http://ClinicalTrials.gov/show/NCT01218516>

Study 178:

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

<http://ClinicalTrials.gov/show/NCT01378975>

Study 179:

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT00911326>

Study 180:

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

<http://ClinicalTrials.gov/show/NCT01023880>

Study 181:

A Study of Siltuximab (Anti-IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01484275>

Study 182:

Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01239797>

Study 183:

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01335399>

Study 184:

An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

<http://ClinicalTrials.gov/show/NCT00947856>

Study 185:

Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01383928>

Study 186:

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00821249>

Study 187:

A Study of MLN9708 Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01217957>

Study 188:

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01271504>

Study 189:

Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01191801>

Study 190:

Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00461045>

Study 191:

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01478048>

Study 192:

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

<http://ClinicalTrials.gov/show/NCT01393964>

Study 193:

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01456689>

Study 194:

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01223027>

Study 195:

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

<http://ClinicalTrials.gov/show/NCT01480479>

Study 196:

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

<http://ClinicalTrials.gov/show/NCT01215136>

Study 197:

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01108445>

Study 198:

Study of Denileukin Diftitox in Patients With Stage IIC and Stage IV Melanoma

<http://ClinicalTrials.gov/show/NCT01127451>

Study 199:

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

<http://ClinicalTrials.gov/show/NCT01208662>

Study 200:

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01029054>

Study 201:

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

<http://ClinicalTrials.gov/show/NCT01310816>

Study 202:

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

<http://ClinicalTrials.gov/show/NCT01158885>

Study 203:

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00135200>

Study 204:

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

<http://ClinicalTrials.gov/show/NCT00615589>

Study 205:

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor

<http://ClinicalTrials.gov/show/NCT01369329>

Study 206:

Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

<http://ClinicalTrials.gov/show/NCT01441635>

Study 207:

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

<http://ClinicalTrials.gov/show/NCT00687765>

Study 208:

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

<http://ClinicalTrials.gov/show/NCT01343277>

Study 209:

Phase I Biomarker Study (BMS-936558)

<http://ClinicalTrials.gov/show/NCT01358721>

Study 210:

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

<http://ClinicalTrials.gov/show/NCT00585312>

Study 211:

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

<http://ClinicalTrials.gov/show/NCT00944905>

Study 212:

A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01297244>

Study 213:

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

<http://ClinicalTrials.gov/show/NCT01140347>

Study 214:

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01210495>

Study 215:

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

<http://ClinicalTrials.gov/show/NCT01136967>

Study 216:

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01327053>

Study 217:

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

<http://ClinicalTrials.gov/show/NCT00782067>

Study 218:

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01034631>

Study 219:

A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

<http://ClinicalTrials.gov/show/NCT00210665>

Study 220:

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

<http://ClinicalTrials.gov/show/NCT01141491>

Study 221:

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

<http://ClinicalTrials.gov/show/NCT01168791>

Study 222:

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

<http://ClinicalTrials.gov/show/NCT01505608>

Study 223:

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

<http://ClinicalTrials.gov/show/NCT01483820>

Study 224:

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

<http://ClinicalTrials.gov/show/NCT01232556>

Study 225:

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

<http://ClinicalTrials.gov/show/NCT01100502>

Study 226:

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

<http://ClinicalTrials.gov/show/NCT01087151>

Study 227:

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01363297>

Study 228:

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

<http://ClinicalTrials.gov/show/NCT00601003>

Study 229:

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

<http://ClinicalTrials.gov/show/NCT00644696>

Study 230:

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

<http://ClinicalTrials.gov/show/NCT01112527>

Study 231:

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

<http://ClinicalTrials.gov/show/NCT00752206>

Study 232:

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT01460160>

Study 233:

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

<http://ClinicalTrials.gov/show/NCT01241500>

Study 234:

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

<http://ClinicalTrials.gov/show/NCT00931918>

Study 235:

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01482962>

Study 236:

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01197560>

Study 237:

Dasatinib Combo With SMO Inhibitor (BMS-833923)

<http://ClinicalTrials.gov/show/NCT01218477>

Study 238:

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

<http://ClinicalTrials.gov/show/NCT01242488>

Study 239:

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT00963105>

Study 240:

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

<http://ClinicalTrials.gov/show/NCT01275209>

Study 241:

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

<http://ClinicalTrials.gov/show/NCT01519011>

Study 242:

Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen

<http://ClinicalTrials.gov/show/NCT01077518>

Study 243:

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

<http://ClinicalTrials.gov/show/NCT00737529>

Study 244:

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT01209130>

Study 245:

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

<http://ClinicalTrials.gov/show/NCT01321541>

Study 246:

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

<http://ClinicalTrials.gov/show/NCT00990054>

Study 247:

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

<http://ClinicalTrials.gov/show/NCT01357655>

Study 248:

A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma
<http://ClinicalTrials.gov/show/NCT01414855>

Study 249:

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
<http://ClinicalTrials.gov/show/NCT00911066>

Study 250:

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
<http://ClinicalTrials.gov/show/NCT01039376>

Study 251:

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
<http://ClinicalTrials.gov/show/NCT01466179>

Study 252:

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
<http://ClinicalTrials.gov/show/NCT01200589>

Study 253:

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
<http://ClinicalTrials.gov/show/NCT01265199>

Study 254:

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma
<http://ClinicalTrials.gov/show/NCT01528865>

Study 255:

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease
<http://ClinicalTrials.gov/show/NCT01188889>

Study 256:

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
<http://ClinicalTrials.gov/show/NCT00981799>

Study 257:

Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
<http://ClinicalTrials.gov/show/NCT00777114>

Study 258:

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
<http://ClinicalTrials.gov/show/NCT01029730>

Study 259:

Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen
<http://ClinicalTrials.gov/show/NCT01457885>

Study 260:

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
<http://ClinicalTrials.gov/show/NCT00703820>

Study 261:

A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
<http://ClinicalTrials.gov/show/NCT01411267>

Study 262:

Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
<http://ClinicalTrials.gov/show/NCT01389076>

Study 263:

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

<http://ClinicalTrials.gov/show/NCT01541553>

Study 264:

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

<http://ClinicalTrials.gov/show/NCT00940602>

Study 265:

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

<http://ClinicalTrials.gov/show/NCT01137682>

Diabetes

(33 clinical trials recruiting)

Study 1:

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT00658021>

Study 2:

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01243424>

Study 3:

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

<http://ClinicalTrials.gov/show/NCT01195662>

Study 4:

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

<http://ClinicalTrials.gov/show/NCT01137474>

Study 5:

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

<http://ClinicalTrials.gov/show/NCT01131676>

Study 6:

Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

<http://ClinicalTrials.gov/show/NCT01422876>

Study 7:

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01144338>

Study 8:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

<http://ClinicalTrials.gov/show/NCT00968708>

Study 9:

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01351675>

Study 10:

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01494987>

Study 11:

A Study With Alogliptin in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01042769>

Study 12:

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01414920>

Study 13:

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

<http://ClinicalTrials.gov/show/NCT01499082>

Study 14:

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

<http://ClinicalTrials.gov/show/NCT01499095>

Study 15:

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

<http://ClinicalTrials.gov/show/NCT01570751>

Study 16:

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01204775>

Study 17:

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

<http://ClinicalTrials.gov/show/NCT01394952>

Study 18:

Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01289990>

Study 19:

BMS—Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

<http://ClinicalTrials.gov/show/NCT01498185>

Study 20:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

<http://ClinicalTrials.gov/show/NCT01434186>

Study 21:

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01472185>

Study 22:

Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01456195>

Study 23:

Efficacy and Safety of TAK-875 Compared to Glimpiride When Used With Metformin in Participants With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01481116>

Study 24:

Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT00789750>

Study 25:

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01183013>

Study 26:

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

<http://ClinicalTrials.gov/show/NCT01487109>

Study 27:

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

<http://ClinicalTrials.gov/show/NCT01308437>

Study 28:

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

<http://ClinicalTrials.gov/show/NCT01356849>

Study 29:

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

<http://ClinicalTrials.gov/show/NCT01496365>

Study 30:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

<http://ClinicalTrials.gov/show/NCT01147250>

Study 31:

Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

<http://ClinicalTrials.gov/show/NCT01474772>

Study 32:

A Study to Evaluate the Efficacy and Safety of a Single Application of QUTENZA Compared to That of Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

<http://ClinicalTrials.gov/show/NCT01533428>

Study 33:

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

<http://ClinicalTrials.gov/show/NCT01521598>

Heart Disease

(45 clinical trials recruiting)

Study 1:

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

<http://ClinicalTrials.gov/show/NCT01516541>

Study 2:

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

<http://ClinicalTrials.gov/show/NCT01245634>

Study 3:

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

<http://ClinicalTrials.gov/show/NCT01323153>

Study 4:

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/ Emergency Department Visits or Cardiovascular Death in Patients With Implantable Cardioverter Defibrillators (ICDs)

<http://ClinicalTrials.gov/show/NCT01464476>

Study 5:

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

<http://ClinicalTrials.gov/show/NCT01508910>

Study 6:

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01042769>

Study 7:

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

<http://ClinicalTrials.gov/show/NCT00683696>

Study 8:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

<http://ClinicalTrials.gov/show/NCT01225562>

Study 9:

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects Who Need Aortic Valve Replacement

<http://ClinicalTrials.gov/show/NCT01531374>

Study 10:

Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter

<http://ClinicalTrials.gov/show/NCT01253200>

Study 11:

The Evaluation of VAD InterVENTion Before Inotropic Therapy

<http://ClinicalTrials.gov/show/NCT01369407>

Study 12:

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

<http://ClinicalTrials.gov/show/NCT00990327>

Study 13:

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

<http://ClinicalTrials.gov/show/NCT01313572>

Study 14:

RED-HF™ Trial—Reduction of Events With Darbeopetin Alfa in Heart Failure Trial

<http://ClinicalTrials.gov/show/NCT00358215>

Study 15:

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD

<http://ClinicalTrials.gov/show/NCT01347710>

Study 16:

Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions

<http://ClinicalTrials.gov/show/NCT01092416>

Study 17:

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

<http://ClinicalTrials.gov/show/NCT01334918>

Study 18:

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure

<http://ClinicalTrials.gov/show/NCT01300013>

Study 19:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

<http://ClinicalTrials.gov/show/NCT00968708>

Study 20:

AngelMed for Early Recognition and Treatment of STEMI

<http://ClinicalTrials.gov/show/NCT00781118>

Study 21:

Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy

<http://ClinicalTrials.gov/show/NCT01121107>

Study 22:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

<http://ClinicalTrials.gov/show/NCT01147250>

Study 23:

Increase Of VAgal TonE in CHF

<http://ClinicalTrials.gov/show/NCT01303718>

Study 24:

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients—Efficacy and Safety: The CHI SQUARE Trial

<http://ClinicalTrials.gov/show/NCT01201837>

Study 25:

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

<http://ClinicalTrials.gov/show/NCT01096043>

Study 26:

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

<http://ClinicalTrials.gov/show/NCT01076764>

Study 27:

ABLATE AF Registry Trial

<http://ClinicalTrials.gov/show/NCT01174745>

Study 28:

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

<http://ClinicalTrials.gov/show/NCT01327183>

Study 29:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>

Study 30:

Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

<http://ClinicalTrials.gov/show/NCT01182441>

Study 31:

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

<http://ClinicalTrials.gov/show/NCT01312935>

Study 32:

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

<http://ClinicalTrials.gov/show/NCT01444872>

Study 33:

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

<http://ClinicalTrials.gov/show/NCT00520806>

Study 34:

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

<http://ClinicalTrials.gov/show/NCT01268319>

Study 35:

Premium Migraine Trial

<http://ClinicalTrials.gov/show/NCT00355056>

Study 36:

Post-Myocardial Infarction Remodeling Prevention Therapy

<http://ClinicalTrials.gov/show/NCT01213251>

Study 37:

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure

<http://ClinicalTrials.gov/show/NCT00853658>

Study 38:

A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

<http://ClinicalTrials.gov/show/NCT01357850>

Study 39:

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

<http://ClinicalTrials.gov/show/NCT01314313>

Study 40:

AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

<http://ClinicalTrials.gov/show/NCT01495364>

Study 41:

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System—Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

<http://ClinicalTrials.gov/show/NCT01456000>

Study 42:

Clarification of Optimal Anticoagulation Through Genetics

<http://ClinicalTrials.gov/show/NCT00839657>

Study 43:

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

<http://ClinicalTrials.gov/show/NCT01165580>

Study 44:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Study 45:

Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

<http://ClinicalTrials.gov/show/NCT00886743>

Mental Illness

(28 clinical trials recruiting)

Study 1:

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

<http://ClinicalTrials.gov/show/NCT01470469>

Study 2:

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

<http://ClinicalTrials.gov/show/NCT01106430>

Study 3:

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

<http://ClinicalTrials.gov/show/NCT01081132>

Study 4:

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

<http://ClinicalTrials.gov/show/NCT01418339>

Study 5:

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

<http://ClinicalTrials.gov/show/NCT01244490>

Study 6:

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

<http://ClinicalTrials.gov/show/NCT00550238>

Study 7:

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

<http://ClinicalTrials.gov/show/NCT01174004>

Study 8:

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

<http://ClinicalTrials.gov/show/NCT01122927>

Study 9:

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

<http://ClinicalTrials.gov/show/NCT00667810>

Study 10:

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01127633>

Study 11:

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

<http://ClinicalTrials.gov/show/NCT00998764>

Study 12:

A Long-Term, Open-Label, Study on Schizophrenia

<http://ClinicalTrials.gov/show/NCT01129674>

Study 13:

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01193608>

Study 14:

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01369225>

Study 15:

A Study of LY2140023 in Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01307800>

Study 16:

Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM2)

<http://ClinicalTrials.gov/show/NCT01349907>

Study 17:

A Study in Pediatric Patients With Generalized Anxiety Disorder

<http://ClinicalTrials.gov/show/NCT01226511>

Study 18:

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907)}(P06107 AM2)

<http://ClinicalTrials.gov/show/NCT01244815>

Study 19:

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

<http://ClinicalTrials.gov/show/NCT01429116>

Study 20:

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

<http://ClinicalTrials.gov/show/NCT01163032>

Study 21:

A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

<http://ClinicalTrials.gov/show/NCT01432236>

Study 22:

Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896 AM2)

<http://ClinicalTrials.gov/show/NCT01190254>

Study 23:

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

<http://ClinicalTrials.gov/show/NCT01430754>

Study 24:

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

<http://ClinicalTrials.gov/show/NCT01149655>

Study 25:

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

<http://ClinicalTrials.gov/show/NCT01521663>

Study 26:

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897 AM2 EXT)

<http://ClinicalTrials.gov/show/NCT01190267>

Study 27:

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01492374>

Study 28:

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT00235716>

Stroke

(9 clinical trials recruiting)

Study 1:

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

<http://ClinicalTrials.gov/show/NCT00856661>

Study 2:

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

<http://ClinicalTrials.gov/show/NCT00106938>

Study 3:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

<http://ClinicalTrials.gov/show/NCT01225562>

Study 4:

Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

<http://ClinicalTrials.gov/show/NCT01182441>

Study 5:

Clarification of Optimal Anticoagulation Through Genetics

<http://ClinicalTrials.gov/show/NCT00839657>

Study 6:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

<http://ClinicalTrials.gov/show/NCT00968708>

Study 7:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Study 8:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>

Study 9:

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

<http://ClinicalTrials.gov/show/NCT01344447>



Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004

www.phrma.org

